<DOC>
	<DOC>NCT02786745</DOC>
	<brief_summary>To find out the safety and effectiveness of dapsone.</brief_summary>
	<brief_title>Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris</brief_title>
	<detailed_description>The purpose of the study is to find out more about the safety and effectiveness of an investigational drug called Dapsone gel for patients with acne vulgaris.</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Adolescent or adult male and female patients who are 12 years of age or older. Acne vulgaris patients with minimum of 20 but not more than 50 inflammatory lesions on the face; a minimum of 30 but not more than 100 noninflammatory lesions. Patients with an acne grade of 3(moderate) A negative uring pregnancy test result for females of childbearing potential at the screening and day 1 visits. Patient is in good health as determined by medical history, physical examination, and vital signs. Patient is willing to avoid excessive or prolonged exposure of the treated skin to ultraviolet throughout the study. Patient is willing to follow study instructions, complete study assessments without any assistance, and likely to complete all required visits. Uncontrolled systemic disease(s). Severe cystic acne, acne conglobata, acne fulminans, or secondary acne. One or more nodule(s) or cyst(s) above the mandibular line. Using systemic immunosuppressive drugs within 4 weeks prior to screening or anticipated use of any systemic therapy with the potential to affect acne during the study. Any of the following topical procedures or treatments on the face occurring in the specified period prior to baseline(day 1)." 1 week: phototherapy devices, energybased devices, adhesive cleansing strips, or cosmetic procedures. 2 weeks: antiinflammatory drugs, salicylic acid, coricosteroids, antibiotics, antibacterials, retinoids, other topical acne treatments. Any of the following systemic medications taken in the specified period prior to baseline(day 1): 2 weeks: antiinflammatory drugs 4 weeks: antibiotics 6 months: other acne treatments Skin abnormalities (other than acne vulgaris), excessive hair, or other physical characteristics in or around the test sites that could confound the study Patients who have any allergy or sensitivity to the study drugs or its components Females who are pregnant, nursing, or planning a pregnancy during the study or think they may be pregnant at the start of the study Current enrollment in an investigational drug or device study, or participation in such a study whithin 30 days prior to screening for this study Taking oral dapsone or antimalarial medications</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>